Verrica Pharmaceuticals Inc. (VRCA)

Market Cap	39.48M
Revenue (ttm)	14.70M
Net Income (ttm)	-48.60M
Shares Out	9.45M
EPS (ttm)	-6.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,891
Open	4.060
Previous Close	4.090
Day's Range	4.000 - 4.310
52-Week Range	3.816 - 17.500
Beta	1.79
Analysts	Hold
Price Target	60.00 (+1,335.41%)
Earnings Date	Nov 3, 2025

About VRCA

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company’s product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of der...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 15, 2018
• Employees: 71
• Stock Exchange: NASDAQ
• Ticker Symbol: VRCA
• Website: https://www.verrica.com

Financial Performance

In 2024, Verrica Pharmaceuticals's revenue was $7.57 million, an increase of 47.66% compared to the previous year's $5.12 million. Losses were -$76.58 million, 14.3% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for VRCA stock is "Hold." The 12-month stock price target is $60.0, which is an increase of 1,335.41% from the latest price.

Price Target

$60.0

(1,335.41% upside)

Analyst Consensus: Hold